Xie Ming-Guo, Wang Xiong-Fei, Qiao Jiao, Zhou Jian, Guan Yu-Guang, Li Tian-Fu, Qi Xue-Ling, Luan Guo-Ming
Department of Neurosurgery, Epilepsy Center, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Beijing Key Laboratory of Epilepsy, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Front Mol Neurosci. 2023 Feb 23;16:1022364. doi: 10.3389/fnmol.2023.1022364. eCollection 2023.
The aim of the study was to evaluate the clinicopathological features, as well as the surgical prognosis, of epilepsy-associated gangliogliomas (GG) with CD34 expression and BRAF mutation.
Clinical data of patients who underwent epilepsy surgery for GG were retrospectively studied. Univariate and multivariate analyses were performed to evaluate the correlations of clinical and pathological factors with molecular markers of CD34 expression and BRAF mutation in GG.
A total of 208 patients with GG had immunohistochemical detection of CD34 expression (positive/negative: 184/24), and among them, 89 patients had immunohistochemical detection of BRAF mutation (positive/negative: 54/35). By univariate and multivariate analyses, seizure aura ( = 0.025), concordance of ictal electroencephalogram (EEG) findings ( = 0.045) and medial temporal tumor ( = 0.030) were found to be related to CD34 expression, but only hospitalization time ( = 0.042) was different for BRAF-mutated status. In addition, drug-resistant epilepsy ( = 0.040) and concordance of interictal EEG findings ( = 0.009) were found to be associated with tumor progression-free survival (PFS) in univariate analysis, but only concordance of interictal EEG findings was with significance in multivariate analysis. However, CD34 expression or BRAF mutation in GG was not found to be associated with surgical outcomes of seizure control and tumor PFS.
The CD34 expression or BRAF mutation in GG may partly influence the distribution of clinicopathological features of patients with epilepsy, but they may be not able to predict the surgical prognosis of seizure outcome and tumor recurrence.
本研究旨在评估具有CD34表达和BRAF突变的癫痫相关性神经节细胞胶质瘤（GG）的临床病理特征及手术预后。
回顾性研究因GG接受癫痫手术患者的临床资料。进行单因素和多因素分析，以评估临床和病理因素与GG中CD34表达和BRAF突变分子标志物的相关性。
共有208例GG患者接受了CD34表达的免疫组化检测（阳性/阴性：184/24），其中89例患者接受了BRAF突变的免疫组化检测（阳性/阴性：54/35）。通过单因素和多因素分析，发现癫痫先兆（=0.025）、发作期脑电图（EEG）结果的一致性（=0.045）和颞叶内侧肿瘤（=0.030）与CD34表达相关，但BRAF突变状态仅住院时间（=0.042）不同。此外，单因素分析发现耐药性癫痫（=0.040）和发作间期EEG结果的一致性（=0.009）与无肿瘤进展生存期（PFS）相关，但多因素分析中只有发作间期EEG结果的一致性具有显著性。然而，未发现GG中的CD34表达或BRAF突变与癫痫发作控制和肿瘤PFS的手术结果相关。
GG中的CD34表达或BRAF突变可能部分影响癫痫患者临床病理特征的分布，但它们可能无法预测癫痫发作结果和肿瘤复发的手术预后。
